Thus, TGF-β1 is considered as a potential biomarker for renal fibrosis and inhibiting TGF-β1/Smad2/3 pathway may represent an effective therapy for DN associated with progressive real fibrosis [9]. Here, SMAD2 is linked to renal fibrosis.